rs780999703
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP2BS3
This summary comes from the ClinGen Evidence Repository: NM_001754.5(RUNX1):c.668A>G (p.Glu223Gly) is a missense variant predicted to cause the substitution of glutamic acid by glycine at amino acid 223 (p.E223G). The highest population minor allele frequency in gnomAD v2 is 0.0001146 (13/113452 alleles) in the non-Finnish European population (PM2_Supporting, BS1, and BA1 are not met). This variant has also been observed in gnomAD v3/v4 in one homozygous individual of Finnish descent, and there are no known reports of affected patients with homozygous RUNX1 variants, plus RUNX1-null mice do not survive (BP2). The germline variant has been published in 2-3 children with B-ALL (PMID:26580448; PMID:34166225) and in a 22-year-old female with thrombocytopenia (low platelet count) and mild bleeding (menorrhagia), congenital aortic valve abnormality, and periventricular nodular heterotopia of the cerebrum but a negative family history of thrombocytopenia and hematologic malignancy (DOI: 10.1155/2023/4738660). However, the variant's presence in the general population (gnomAD) precludes the application of PS4 at any strength level. The computational predictor REVEL gives a score of 0.799, which is neither above nor below the thresholds predicting a damaging or benign impact on RUNX1 function. However, in vitro functional data indicate that the mutant protein exhibits normal transcriptional activity in a luciferase reporter assay using U937 cells (~105-115% of WT activity, Fig. 4), normal DNA-binding and β-subunit interaction in an EMSA assay using Cos7 cells (Fig. 2), appropriate nuclear localization in NIH3T3 cells, and normal ubiquitination (Fig. 5) (PMID:23817177) (BS3). In summary, this variant meets the criteria to be classified as likely benign for autosomal dominant hereditary thrombocytopenia and hematologic cancer predisposition syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy VCEP: BP2 and BS3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10014381/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RUNX1 | NM_001754.5 | c.668A>G | p.Glu223Gly | missense_variant | 7/9 | ENST00000675419.1 | NP_001745.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RUNX1 | ENST00000675419.1 | c.668A>G | p.Glu223Gly | missense_variant | 7/9 | NM_001754.5 | ENSP00000501943 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000931 AC: 14AN: 150354Hom.: 1 Cov.: 31
GnomAD3 exomes AF: 0.000124 AC: 31AN: 250952Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135626
GnomAD4 exome AF: 0.0000719 AC: 105AN: 1460854Hom.: 0 Cov.: 32 AF XY: 0.0000757 AC XY: 55AN XY: 726718
GnomAD4 genome AF: 0.0000931 AC: 14AN: 150354Hom.: 1 Cov.: 31 AF XY: 0.0000957 AC XY: 7AN XY: 73150
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2022 | RUNX1: PP3, BS1 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 22, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26580448, Nitschke2022[poster], Nitschke2023[article], 31289210, 34166225) - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Sep 24, 2021 | - - |
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Benign:1
Likely benign, reviewed by expert panel | curation | ClinGen Myeloid Malignancy Variant Curation Expert Panel | Sep 18, 2024 | NM_001754.5(RUNX1):c.668A>G (p.Glu223Gly) is a missense variant predicted to cause the substitution of glutamic acid by glycine at amino acid 223 (p.E223G). The highest population minor allele frequency in gnomAD v2 is 0.0001146 (13/113452 alleles) in the non-Finnish European population (PM2_Supporting, BS1, and BA1 are not met). This variant has also been observed in gnomAD v3/v4 in one homozygous individual of Finnish descent, and there are no known reports of affected patients with homozygous RUNX1 variants, plus RUNX1-null mice do not survive (BP2). The germline variant has been published in 2-3 children with B-ALL (PMID: 26580448; PMID: 34166225) and in a 22-year-old female with thrombocytopenia (low platelet count) and mild bleeding (menorrhagia), congenital aortic valve abnormality, and periventricular nodular heterotopia of the cerebrum but a negative family history of thrombocytopenia and hematologic malignancy (DOI: 10.1155/2023/4738660). However, the variant's presence in the general population (gnomAD) precludes the application of PS4 at any strength level. The computational predictor REVEL gives a score of 0.799, which is neither above nor below the thresholds predicting a damaging or benign impact on RUNX1 function. However, in vitro functional data indicate that the mutant protein exhibits normal transcriptional activity in a luciferase reporter assay using U937 cells (~105-115% of WT activity, Fig. 4), normal DNA-binding and β-subunit interaction in an EMSA assay using Cos7 cells (Fig. 2), appropriate nuclear localization in NIH3T3 cells, and normal ubiquitination (Fig. 5) (PMID: 23817177) (BS3). In summary, this variant meets the criteria to be classified as likely benign for autosomal dominant hereditary thrombocytopenia and hematologic cancer predisposition syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy VCEP: BP2 and BS3. - |
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at